| Literature DB >> 25857258 |
S Young1, O Sedgwick2, M Fridman3, G Gudjonsson4, P Hodgkins5, M Lantigua6, R A González1.
Abstract
BACKGROUND: Rates of psychiatric disorders are highly prevalent among prison inmates, and recent evidence confirms over-representation of youths and adults with attention deficit hyperactivity disorder (ADHD). The risk for psychiatric co-morbidity may be greater among offenders with ADHD. We undertook a systematic review and meta-analysis of reported rates of co-existing psychiatric morbidity with ADHD in prison samples.Entities:
Keywords: ADHD; co-morbidity; meta-analysis; prison; substance use disorders
Mesh:
Year: 2015 PMID: 25857258 PMCID: PMC4531473 DOI: 10.1017/S0033291715000598
Source DB: PubMed Journal: Psychol Med ISSN: 0033-2917 Impact factor: 7.723
Fig. 1.Flow diagram of the manual screening process for eligible literature inclusion.
Summary of characteristics of studies included in the meta-analyses, by psychiatric disorders and pooled co-morbidity rates, by psychiatric disorders
| Study (year) | Gender | Age group | Age ( | ADHD/total | Co-morbidity/total | Co-morbidity rates/ADHD |
|---|---|---|---|---|---|---|
| Conduct disorder | ||||||
| Chang | Males | ⩽18 | 17.7 | 37/59 | 44/59 | 24/37 |
| Gordon & Moore ( | Males | ⩽18 | 16.0 | 92/453 | 247/453 | 53/92 |
| Kaplan & Cornell ( | Males | ⩽18 | 16.0 | 30/122 | 52/122 | 7/30 |
| Stahlberg | Mixed | ⩽18 | 16.3 | 47/100 | 77/100 | 36/47 |
| Young | Males | ⩽18 | 14.6 | 23/54 | 33/54 | 19/23 |
| Grieger & Hosser ( | Males | Adult | 19.0 | 55/275 | 58/275 | 15/55 |
| Westmoreland | Mixed | Adult | 29.2 | 68/319 | 56/319 | 21/68 |
| Substance use disorders | ||||||
| Abram | Males | ⩽18 | 14.0 | 524/1170 | 604/1170 | 387/524 |
| Abram | Females | ⩽18 | 14.0 | 317/656 | 303/656 | 205/317 |
| Gordon & Moore ( | Males | ⩽18 | 16.0 | 92/453 | 351/453 | 74/92 |
| Milin | Mixed | ⩽18 | 15.5 | 21/111 | 90/111 | 21/21 |
| Stahlberg | Mixed | ⩽18 | 16.3 | 47/100 | 55/100 | 25/47 |
| Einarsson | Males | Adult | 31.0 | 27/90 | 55/90 | 22/27 |
| Grieger & Moore ( | Males | Adult | 19.0 | 55/275 | 89/275 | 18/55 |
| Konstenius | Females | Adult | 39.7 | 16/56 | 39/56 | 16/16 |
| Retz | Males | Adult | 18.8 | 28/129 | 109/129 | 25/28 |
| Rosler | Females | Adult | 34.0 | 11/94 | 49/94 | 9/11 |
| Westmoreland | Mixed | Adult | 29.2 | 68/319 | 286/319 | 67/68 |
| Young | Males | Adult | 30.0 | 27/198 | 108/198 | 16/27 |
| Mood disorders | ||||||
| Abram | Males | ⩽18 | 14.0 | 524/1170 | 150/1170 | 145/524 |
| Abram | Females | ⩽18 | 14.0 | 317/656 | 144/656 | 102/317 |
| Anckarsater | Mixed | ⩽18 | 16.2 | 51/130 | 17/130 | 4/51 |
| Chang | Males | ⩽18 | 17.7 | 37/59 | 6/59 | 5/37 |
| Gordon & Moore ( | Males | ⩽18 | 16.0 | 92/453 | 148/453 | 39/92 |
| Plattner | Males | ⩽18 | 16.5 | 108/266 | 50/266 | 29/108 |
| Plattner | Females | ⩽18 | 17.8 | 17/53 | 19/53 | 8/17 |
| Stahlberg | Mixed | ⩽18 | 16.3 | 47/100 | 20/100 | 14/47 |
| Einarsson | Males | Adult | 31.0 | 27/90 | 29/90 | 13/27 |
| Eyestone & Howell ( | Males | Adult | 40.0 | 48/88 | 49/88 | 38/48 |
| Konstenius | Females | Adult | 39.7 | 16/56 | 24/56 | 9/16 |
| Rosler | Females | Adult | 34.0 | 11/94 | 53/94 | 8/11 |
| Westmoreland | Mixed | Adult | 29.2 | 68/319 | 173/319 | 59/68 |
| Young | Males | Adult | 30.0 | 27/196 | 38/196 | 12/27 |
| Depressive disorder | ||||||
| Anckarsater | Mixed | ⩽18 | 16.2 | 51/130 | 17/130 | 4/51 |
| Chang | Males | ⩽18 | 17.7 | 37/59 | 6/59 | 5/37 |
| Gordon & Moore ( | Males | ⩽18 | 16.0 | 86/436 | 20/436 | 6/86 |
| Stahlberg | Mixed | ⩽18 | 16.3 | 47/100 | 20/100 | 14/47 |
| Einarsson | Males | Adult | 31.0 | 27/90 | 19/90 | 9/27 |
| Eyestone & Howell ( | Males | Adult | 40.0 | 48/88 | 49/88 | 38/48 |
| Konstenius | Females | Adult | 39.7 | 16/56 | 24/56 | 9/16 |
| Westmoreland | Mixed | Adult | 29.2 | 68/319 | 74/319 | 34/68 |
| Young | Males | Adult | 30.0 | 27/196 | 21/196 | 8/27 |
| Anxiety disorders | ||||||
| Abram | Males | ⩽18 | 14.0 | 524/1170 | 230/1170 | 182/524 |
| Abram | Females | ⩽18 | 14.0 | 317/656 | 206/656 | 126/317 |
| Chang | Males | ⩽18 | 17.7 | 37/59 | 15/59 | 5/37 |
| Stahlberg | Mixed | ⩽18 | 16.3 | 47/100 | 18/100 | 6/47 |
| Einarsson | Males | Adult | 31.0 | 27/90 | 24/90 | 11/27 |
| Rosler | Females | Adult | 34.0 | 11/94 | 50/94 | 8/11 |
| Westmoreland | Mixed | Adult | 29.2 | 68/319 | 136/319 | 46/68 |
| Young | Males | Adult | 30.0 | 27/198 | 120/198 | 24/27 |
| Personality disorders | ||||||
| Black | Mixed | Adult | 30.7 | 68/320 | 113/320 | 37/68 |
| Einarsson | Males | Adult | 31.0 | 27/90 | 52/90 | 23/27 |
| Konstenius | Females | Adult | 39.7 | 16/56 | 25/56 | 13/16 |
| Retz | Males | Adult | 18.8 | 28/129 | 27/129 | 6/28 |
| Rosler | Females | Adult | 34.0 | 11/94 | 28/94 | 7/11 |
| Westmoreland | Mixed | Adult | 29.2 | 68/319 | 112/319 | 37/68 |
| Young | Males | Adult | 30.0 | 27/198 | 141/198 | 24/27 |
ADHD, Attention deficit hyperactivity disorder
Not included in the meta-analytic prevalence rate because of one 0 count cell.
There were two missing cases on these co-morbidity rates.
17 cases excluded as questionable depression.
Only adult studies included.
Pooled random effects meta-analysis estimates of the prevalence of psychiatric disorders co-existing with ADHD
| ⩽18years | Adults | |||
|---|---|---|---|---|
| Psychiatric co-morbidity | Rate | 95% CI | Rate | 95% CI |
| Conduct disorder | 0.61 | 0.43–0.80 | 0.29 | 0.21–0.37 |
| Substance use disorders | 0.70 | 0.59–0.80 | 0.74 | 0.52–0.96 |
| Mood disorders | 0.25 | 0.16–0.34 | 0.66 | 0.50–0.81 |
| Depressive disorder | 0.13 | 0.05–0.21 | 0.55 | 0.35–0.76 |
| Anxiety disorders | 0.21 | 0.03–0.40 | 0.68 | 0.48–0.88 |
| Personality disorders | – | – | 0.60 | 0.41–0.78 |
ADHD, Attention deficit hyperactivity disorder; CI, confidence interval.
Only adult studies included.
Fig. 2.Forest plots with overall odds ratios (OR), effect size (ES), and homogeneity statistics for meta-analyses of six domains of co-morbid disorders.
Fig. 3.Forest plots with odds ratios (OR), effect size (ES), and homogeneity statistics for meta-analyses of five domains of co-morbid disorders stratified by age ⩽18 years and adult studies. Only adult studies for personality disorders, included in Fig. 2.